Find Clinical Trials

Inclusion Criteria: * at least 18 years old * willing to undergo vascular assessments * informed consent signed Exclusion Criteria: * Unwilling to provide informed consent * Open-angle glaucoma * Epilepsia * (gestational) Diabetes * Multiple pregnancies * Fetal malformations * Hypercholesterolemia * Kidney disease * Auto-immune disorders * Connective tissue diseases

Inclusion Criteria: 1. Age ≥18 years of age at the time of signing the informed consent 2. Body mass index (BMI) ≥27 kg/m2 3. Have Type 2 Diabetes Mellitus according to the American Diabetes Association with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Type 2 diabetes mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists Exclusion Criteria: 1. History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation 2. Self-reported body weight change of 5% or more within 3 months of screening 3. Have a prior or planned surgical treatment for obesity (except for liposuction or abdominoplasty if performed \>1 year prior to screening) 4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line) 5. Have Type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 diabetes mellitus (T2DM) 6. Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening • Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG \< 54 mg/dL 7. Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values \> 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization 8. Have proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment 9. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) 10. History of acute or chronic pancreatitis 11. Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening

Inclusion Criteria: * Aged between 20 and 65 years * Diagnosed with PTSD according to DSM-5 criteria * Score ≥ 33 on the PTSD Checklist for DSM-5 (PCL-5) * Able to provide informed consent * Stable psychiatric medication regimen (if any) for at least 4 weeks prior to enrollment Exclusion Criteria: * Diagnosed with schizophrenia, schizoaffective disorder, or bipolar I disorder * Current substance dependence or abuse within the past 6 months * Severe suicidal ideation or suicide attempt in the past 6 months * Cognitive impairment or neurological disorder affecting participation * Concurrent participation in other psychological treatment for PTSD

Inclusion Criteria: * The general inclusion criteria involve being 18+, speaking English or Spanish, and meeting one or more of the following criteria: Obesity: Patients with a body mass index of 30 kg/m2 or greater (i.e., obese category). Cancer screening: Average-risk patients without recommended colorectal or cervical cancer screenings for their age group and biological sex. Specifically: Colon Cancer (CRC) inclusion criteria: Patients aged 45-75 who are due for screenings, with last FIT longer than 1 year ago, last colonoscopy longer than 10 years ago, and last Cologuard longer than 3 years ago. And/or Cervical cancer inclusion criteria: Women and patients with a cervix aged 30-65 who are due for screening: with last pap longer than 3 years ago; last co-test longer than 5 years ago; last primary HPV screening longer than 5 years ago. Mental health: Patients with moderate to severe depression or anxiety symptoms. Exclusion Criteria: * The general exclusion criteria are: those with current pregnancy, or the participant is cognitively impaired, not having a visit to the primary care clinic in the prior 2 years, and speaking a language other than English or Spanish. Exclusion criteria for obesity intervention: had prior metabolic or bariatric surgery or planning to have this surgery in the next 6 months, currently enrolled in an intensive lifestyle program. Exclusion criteria for cancer screening intervention include: Colon Cancer (CRC) exclusion criteria: has colorectal cancer documented in the problem list; has ulcerative colitis or Crohn's disease documented in the problem list Cervical cancer exclusion criteria: has cervical cancer documented in the problem list; has had a prior hysterectomy. Exclusion criteria for mental health: include patients with active suicidality, active substance use disorder, a history of schizophrenia or bipolar disorder, or who are already receiving behavioral health care (therapy sessions in the past 3 months or an appointment upcoming in the next month).

Inclusion Criteria: * Patients must have histologically confirmed breast cancer, stage I-III as per the American Joint Committee on Cancer (AJCC) 8th edition (Anatomic Staging) * Patients must be planned to receive taxane-based regimen for breast cancer (Adjuvant or neoadjuvant) of at least 12 weeks duration. Patients planned to receive taxanes in combination with other chemotherapy drugs (including platinums) are eligible. Patients planned to receive taxanes plus single or dual antiher2 therapy are also eligible. Patients planned to receive taxane-based regimen with immune checkpoint inhibitors are also allowed * Age ≥18 years * Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥60%) * Patients must have an adequate organ and marrow function as defined below: * absolute neutrophil count ≥1,000/microliter (mcL) * platelets ≥100,000/mcL * total bilirubin ≤ institutional upper limit of normal (ULN) * AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN * Creatinine ≤ institutional ULN * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Patients with prior diagnosis of diabetes mellitus are allowed if the patient has no peripheral neuropathy * Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants * Patients must not have received prior taxane or platinum therapy * Women of childbearing potential must have a negative pregnancy test: serum or urine beta human chorionic gonadotropin (hCG) within 14 days prior to first dose of study treatment * Potential fertile subjects must agree to use adequate contraception (double barrier methods of birth control or abstinence) prior to start of treatment, for the duration of treatment, and 28 days after last study medication dose. If male, must also agree to refrain from donating sperm during this period Exclusion Criteria: * Patients with prior diagnosis of peripheral neuropathy * Patients who received chemotherapy for the current breast cancer diagnosis before the planned taxane-based regimen * Patients who are receiving any other investigation agents * Patients with concurrent use of antihistamines during or for 2 days prior to the study period * History of allergic reactions attributed to compounds of similar chemical or biologic composition to desloratadine * Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous * Pregnant or breastfeeding women are not allowed in the study * Patients who are taking probiotics * Patients who are using chronic laxatives or enema * Patients who used antibiotics within 4 weeks of registration

Inclusion Criteria: * aged 18 years or above * the biological father who is expecting or the biological father of infants within 24 months old * experienced mild to moderate anxiety (5 ≤ GAD ≤14) or depression symptoms (5≤ PHQ ≤ 19) * sufficient comprehension of Cantonese * currently live in Hong Kong * able to provide informed consent Exclusion Criteria: * currently experiencing psychosis * having an intellectual disability * experiencing current suicidal ideation * participation in a similar study or received similar services in the past year

Inclusion Criteria: * 21-70 years * Self-identify as Black/African American or Hispanic/Latino * Have Stage 2 CKM defined as: * Systolic BP ≥130mmHg (measured at screening) AND at least one of: * Hypertension (ICD-10: I10-I16) * Prediabetes (HbA1c 5.7-6.4%) or Type 2 Diabetes (HbA1c ≥6.5%) * Stage 3 chronic kidney disease (CKD) (eGFR 30-59 mL/min/1.73m²) * Live in census tracts identified by the Montgomery/ Prince George's/Baltimore City County Departments of Planning as HFPA: * Healthy Food Availability Index score is low (0-9.5), * Median household income ≤185% of Federal Poverty Level * 30% of households have no vehicle, * Distance to supermarket \>1/4 mile. 5. Have refrigeration, food preparation appliances (microwave, stove), and cell phones for the App Exclusion Criteria: * Age \<21 years * Diagnosis of end-stage renal disease (ESRD), dialysis * Serious medical condition that either limits life expectancy or requires active management (e.g., cancer) * Significant food allergies, preferences, intolerances, or dietary requirements that would interfere with diet adherence * Active alcohol or substance use disorder (i.e., not sober/abstinent for ≥ 30 days) * Patients with cognitive impairment or other condition preventing their participation in the intervention * Pregnant, breastfeeding, or planning pregnancy * Current participation in a care management program related to health conditions (e.g., weight reduction, smoking cessation) or another clinical trial that could interfere with the study protocol * Planning to move out of the geographic area in 12 months

Inclusion Criteria: * Adults between the ages of 18 and 65 years * A self-reported principal diagnosis of one or more of the following: schizophrenia (F20), bipolar disorder (F31), personality disorders (F60), obsessive-compulsive disorder (F42), anxiety disorders (F41), recurrent depressive disorder (F33), eating disorders (F50), hyperkinetic disorders (F90), post-traumatic stress disorder (F43.1), Asperger syndrome (F84.5) * Not in full recovery (Brief INSPIRE-O \< 50) * Danish language proficiency * Medication stabilized (i.e., same type and dosage for a minimum of 8 weeks) * Ability and willingness to give informed consent Exclusion Criteria: * Self-reported diagnosis of mental retardation (F70-79) and/or organic mental disorder (F00-09) * Psychiatric symptoms, thoughts of self-harm and/or substance abuse of self-reported severity which are likely to prevent one or all of the following: attendance at scheduled sessions, completion of questionnaires before, during and after the intervention, meaningful engagement in the therapeutic process * Psychiatric hospitalization in the past 4 weeks * Prior conviction of violent crime * Currently homeless * Currently in psychotherapy initiated within the past 6 months.

Inclusion Criteria: 1. Adults aged between 19 and 75 years at the time of providing written informed consent. 2. Diagnosed with type 2 diabetes mellitus and having an HbA1c level between 7.5% and 11.0%. 3. Receiving DPP4 inhibitor monotherapy or combination therapy with metformin and/or sulfonylurea for at least 8 weeks without dose adjustment. 4. Provided written informed consent voluntarily after receiving a full explanation of the study. 5. Considered capable of understanding the study procedures and cooperating throughout the study period until completion. Exclusion Criteria: 1. Patients with diabetes other than type 2 diabetes, including type 1 diabetes or gestational diabetes. 2. Use of TZD or SGLT2 inhibitors within the past 8 weeks, or history of discontinuation due to serious adverse reactions. 3. Currently receiving four or more antidiabetic medications. 4. History of diabetic ketoacidosis (with or without coma) or acute/chronic metabolic acidosis within the past 24 weeks. 5. Known allergy or hypersensitivity to the investigational drugs or their components. 6. Chronic use (more than 14 consecutive days) of oral or parenteral corticosteroids within 8 weeks prior to screening, with ongoing need for dose adjustment. 7. Genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. 8. Active or progressive malignant tumors requiring treatment. 9. History of drug abuse or alcohol dependence within the past 12 weeks. 10. HIV infection. 11. Severe infections, perioperative status, or major trauma. 12. History of heart failure classified as NYHA class III or IV within the past 24 weeks. 13. History of acute cardiovascular events within the past 12 weeks (e.g., unstable angina, myocardial infarction, transient ischemic attack, stroke, coronary artery bypass grafting, or coronary intervention). 14. Renal failure or chronic kidney disease with eGFR \< 25 mL/min/1.73m² or undergoing dialysis. 15. Active bladder cancer or history of bladder cancer. 16. Abnormal liver function defined as serum ALT, AST, or alkaline phosphatase \> 5× ULN, or total bilirubin \> 5× ULN. 17. Pregnant or breastfeeding women. 18. Participation in another clinical trial or administration of investigational drugs within the past 12 weeks (except for observational or retrospective studies deemed not to affect the safety or efficacy of this trial). 19. Determined by the investigator to be unsuitable for participation in the study.

Inclusion Criteria: Adults aged 18 years or older: Participants must be adults, aged 18 years or older, to ensure they are capable of providing informed consent and to focus on adult-onset glaucoma. This age threshold allows the study to target a population where open-angle glaucoma typically manifests, avoiding potential variations in outcomes that might arise in younger populations with different types of ocular conditions. Diagnosis of naive, untreated open-angle glaucoma or similar conditions: The study is restricted to individuals who have been newly diagnosed with primary open-angle glaucoma and have not yet received any form of treatment, either pharmacological or surgical. This ensures that the effects of DSLT (Direct Selective Laser Trabeculoplasty) are evaluated without the confounding influence of prior treatments. Other similar conditions may include ocular hypertension or other early-stage glaucomatous conditions where IOP reduction is indicated (ie: pigment dispersion syndrome/glaucoma and pseudoexfoliation). This broadens the inclusion slightly to capture patients with conditions that have a similar disease mechanism and treatment goal, without including those with more complex or mixed forms of glaucoma. Exclusion Criteria: Previous glaucoma surgeries/interventions: Patients who have undergone prior glaucoma-related surgeries (e.g., trabeculectomy, laser trabeculoplasty, or shunt procedures) or received other significant glaucoma interventions (such as long-term glaucoma medication use) are excluded. This criterion ensures the study evaluates the effect of DSLT in a treatment-naive population. Prior surgeries or interventions could bias the results by introducing variability in eye physiology, making it difficult to attribute outcomes solely to DSLT. Secondary glaucoma or other significant ocular conditions: Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases, are excluded. These conditions often have different pathophysiological mechanisms, which could lead to varied responses to DSLT. Other significant ocular conditions that could interfere with the study include advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function. Excluding these conditions ensures a clearer evaluation of DSLT's effects on open-angle glaucoma without interference from unrelated ocular abnormalities. 3\. Patients who are unable to fixate their head and/or eyes, such as patients suffering from uncontrolled nystagmus, tremors, or similar conditions. 4\. Patients with a pupil that cannot constrict to a diameter of 4 mm or less. In summary, these criteria focus on a specific and controlled population of treatment-naive glaucoma patients to provide a clean evaluation of the effectiveness and safety of DSLT, while excluding individuals whose prior treatments or other conditions could skew the results.

Inclusion Criteria: 1. Age ≥ 18. 2. Documented physician-diagnosed asthma for at least 12 months. 3. Participants who have received asthma controller medication with medium or high dose ICS for at least 6 months. 4. Documented treatment with a total daily dose of either medium or high dose ICS (Refer to Guidelines for the prevention and management of bronchial asthma (2024 edition)) for at least 3 months. 5. At least one additional maintenance asthma controller medication is required according to standard practice of care and must be documented for at least 3 months. 6. Pre-BD FEV1 \< 80% predicted normal. 7. Objective evidence of asthma as documented. 8. Documented history of at least 2 asthma exacerbation events within 12 months, and at least one of the exacerbations should occur during the treatment of medium-to-high dose ICS. 9. ACQ-6 score ≥ 1.5 at screening and on day of baseline. 10. ePRO adherence ≥ 70% in the 7 days prior to randomization. Exclusion Criteria: 1. Clinically significant pulmonary disease other than asthma. 2. History of cancer. 3. History of a clinically significant infection. 4. Current smokers or participants with smoking history ≥ 10 pack-yrs. 5. History of chronic alcohol or drug abuse within 12 months. 6. Hepatitis B, C or HIV. 7. Pregnant or breastfeeding. 8. History of anaphylaxis following any biologic therapy. 9. participant randomized in the current study or previous SHR-1905 studies.

Inclusion Criteria: * Female breast cancer patients aged ≥ 18 years, who are postmenopausal or premenopausal/perimenopausal; * Histologically confirmed HR-positive, HER2-negative early-stage breast cancer (immunohistochemical detection shows ER ≥ 10% and/or PR ≥ 10%, HER2 0-1+ or HER2 ++ but negative and non-amplified by FISH or CISH detection); * Histologically confirmed invasive breast cancer with postoperative pathological stage II-III; * Patients with or without prior neoadjuvant chemotherapy or adjuvant chemotherapy are eligible for enrollment; * The maximum time from surgery to enrollment does not exceed 12 months; * Patients receiving radiotherapy must have recovered from acute radiation reactions, with a washout period of at least 14 days from the end of radiotherapy to enrollment; * Patients who received previous chemotherapy must have recovered from acute adverse reactions of chemotherapy (graded ≤ 1 according to \[CTCAE\]) before enrollment, except for alopecia or grade 2 peripheral neuropathy. There must be a washout period of at least 21 days from the last chemotherapy administration to enrollment; * Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1; * The main organ function levels must meet the following requirements: Blood routine: Neutrophil count (ANC) ≥ 1.5×10⁹/L; Platelet count (PLT) ≥ 90×10⁹/L; Hemoglobin (Hb) ≥ 90 g/L;Blood biochemistry: Total bilirubin (TBIL) ≤ 2.5×ULN; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5×ULN; Alkaline phosphatase ≤ 2.5×ULN; Blood urea nitrogen (BUN) and creatinine (Cr) ≤ 1.5×ULN; * 12-lead electrocardiogram: Fridericia-corrected QT interval (QTcF) \< 470 ms in females (QTcF calculation formula: QTcF = QT/(RR\^1/3)); * Voluntarily participate in this study, sign the informed consent, have good compliance and are willing to cooperate with follow-up. Exclusion Criteria: * Stage IV breast cancer, recurrent or metastatic breast cancer, or inflammatory breast cancer; * A history of any malignant tumor, or having received anti-tumor treatment or radiotherapy for any malignant tumor in the past, excluding cured malignant tumors such as carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin; * Concurrent participation in other clinical trials; * Having received blood transfusion or treatment with colony-stimulating factors, etc. within 2 weeks before enrollment; * Known history of allergy to the components of the drugs in this protocol; * History of immunodeficiency, including positive HIV test, or suffering from other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation; * A history of any heart disease, including: angina pectoris; arrhythmia requiring drug treatment or with clinical significance; myocardial infarction; heart failure; any other heart disease judged by the researcher as unsuitable for participating in this trial; * Pregnant or lactating female patients; * Any other conditions that the researcher deems make the subject unsuitable for participating in this study.

Patients meeting the following criteria will be included in the study: * Histologically or cytologically documented diagnosis of HR-negative and HER2-negative locally recurrent inoperable TNBC (i.e., cannot be treated with curative intent) or advanced/metastatic TNBC from 1 January 2020 to 31 March 2024 * Negative for estrogen receptor with \< 1% of tumor cells positive for estrogen receptor (ER) on immunohistochemistry (IHC) * Negative for progesterone receptor with \< 1% of tumor cells positive for progesterone receptor on IHC * Negative for HER2 with 0 or 1+ intensity on IHC or 2+ intensity on IHC and negative by in situ hybridization per the American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) HER2 guideline * The test documented closest to the diagnosis date should be used as the reference * Aged at least 18 years upon diagnosis of advanced/metastatic TNBC * Known vital status (alive or deceased) as of last available follow-up date documented within the medical record Patients meeting any of the following exclusion criteria will not be eligible for the study: * Diagnosis of other prior primary cancers or malignancies (except nonmelanoma skin cancer) unless curatively treated with no evidence of disease for at least 3 years before diagnosis of advanced/metastatic TNBC * Ever received treatment as part of any clinical trial of an investigational product for cancer * No available medical record entry in the 90 days before or after diagnosis of advanced/metastatic TNBC

Inclusion Criteria: * Having signed the written Informed Consent Form (ICF); * Male or female aged ≥18 years; * Life expectancy ≥12 weeks; * Eastern Cooperative Oncology Group (ECOG) Performance Score 0 or 1; * Patients with histologically or cytologically confirmed locally advanced or metastatic breast cancer, ovarian cancer or other advanced solid tumors who have experienced disease progression, and available standard of care (SOC) therapies had been exhausted; * be willing to provide tumor tissue samples (fresh frozen \[SF\] or previously retained paraffin-embedded \[FFPE\] tumor tissue samples) or peripheral blood germline DNA or ctDNA sample to detect BRCA mutation, or other deficiency in the Homologous Recombination (HR) pathway (by the detection method of next generation sequencing \[NGS\]) * At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; * No serious hematological, cardiopulmonary, or liver or kidney diseases other than the primary disease; * Adequate organ function and bone marrow function. Exclusion Criteria: * Previous or current use of Poly (ADP) ribose glycohydrolase (PARG) inhibitors; * Serious allergy to the study drug or any of its excipients; * Current or previous other malignancy unless treated radically and with no evidence of recurrence or metastasis within the past 5 years; * Central nervous system (CNS) metastasis or meningeal metastasis with clinical symptoms, or other evidence indicating that CNS metastasis or meningeal metastasis has not been adequately controlled; * Patients with Myelodysplastic syndrome (MDS)/Acute myeloid leukemia (AML) or with features suggestive of MDS/AML; * Dysphagia or refractory nausea and vomiting, malabsorption, extracorporeal biliary shunts, or gastrointestinal disorders that affect drug absorption, e.g., Crohn's disease, ulcerative colitis, or short bowel syndrome, or other malabsorption conditions; * Treatment with an anti-cancer small molecule within 5 half-lives (t1/2), or 2 weeks, whichever is shorter; * History of use within 2 weeks prior to the first dose of the study treatment and need to use protocol-prohibited potent inhibitors or potent inducers of cytochrome P450 (CYP) 3A4/BCRP/P-gp during the study; * History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease; * Serious systemic diseases or laboratory abnormalities or other conditions that, at the Investigator's discretion, will make it unsuitable for the patient to participate in this clinical trial.

Inclusion Criteria: 1. Diagnosis: PLWH can be diagnosed if one of the following three items is met according to the Chinese AIDS Diagnosis and Treatment Guidelines (2021): ① HIV antibody screening test positive and HIV supplementation test positive (antibody supplementation test positive or nucleic acid qualitative test positive or nucleic acid quantification\>5000 copies/mL); ② Has a history of epidemiology or clinical manifestations related to AIDS, tested positive for HIV nucleic acid twice; ③ HIV isolation test positive; 2. Receive treatment at the hospital participating in the study; Age range: 18-80 years old, male or female not limited; 3. Patients who are willing to participate in this clinical study and sign the informed consent form for this study. Exclusion Criteria: Individuals who meet any of the following criteria are not eligible to participate in this study: 1. Pregnant or lactating women; Men and women who are preparing for natural conception or artificial assisted reproduction; 2. Severe aphasia, physical disability, or any other non neuropsychological factors that may hinder the completion of the assessment; 3. is currently involved in other research; 4. Having a tendency towards violence may endanger the safety of others.

Inclusion Criteria: * Must be 18 years or older. * Have an interest in Type 2 Diabetes (T2D) prevention OR have a diagnosis of T2D or have risk factors for T2D. * Should not have any chronic disease that could affect participation in the study * Not currently participating in another trial/research study (other than the current one) * Must be a resident of Mississauga Exclusion Criteria: * People under 18 years * Has a Chronic disease that could affect participation in the study * Currently participating in another trial/research study (other than the current one) * Not a resident of Mississauga

Inclusion Criteria: * Are aged 18 years or older. * Are currently being seen by Penn Medicine Thoracic Oncology for lung cancer treatment or survivorship care. * Are referred to collaborative care by a Penn Medicine Thoracic Oncology clinician for treatment of depression, anxiety, or other psycho-therapy services. Exclusion Criteria: * Are already receiving psycho-therapy treatment services outside of Penn Medicine's collaborative care program, Penn Integrated Care (PIC). * Have a significant and/or untreated medical and/or psychiatric co-morbidity (e.g., other cancers, schizophrenia, acute suicidal and/or homicidal ideation) that make them ineligible for the Penn CoCM program.

Inclusion Criteria: * Incident, mild to moderate, ischemic or hemorrhagic stroke (NIHSS≤15, ICH score≤3) * history or new diagnosis of hypertension * ability to read and speak English * internet access * established primary care physician at MGH Exclusion Criteria: * severe stroke (NIHSS\>15, ICH score\>3) * discharge location to inpatient rehabilitation or skilled nursing facility * dementia * subjects with moderate to severe aphasia without a caregiver to consent on their behalf

Inclusion Criteria: * Female, aged 18-75 years * Karnofsky Performance Status ≥60 * Histopathologically confirmed invasive breast adenocarcinoma * Total mastectomy \[with or without nipple-areolar complex preservation\] + axillary dissection/sentinel lymph node biopsy + implant/expander placement R0 resection with negative margins * pT3 or N2-3 disease; or pT1-2N1 * No distant metastasis * Completed standard neoadjuvant/adjuvant chemotherapy cycles * ≤8 weeks post-chemotherapy or ≤12 weeks post-surgery if no chemotherapy * Signed informed consent Exclusion Criteria: * Prior radiotherapy to chest wall or nodal regions * Pregnancy or lactation * T4 stage disease * Autologous breast reconstruction of the irradiated breast * Pre-radiotherapy local/regional/distant metastasis * Grade ≥3 implant-related adverse events irreversible before radiotherapy * Bilateral breast cancer requiring bilateral radiotherapy * Concurrent/secondary malignancy with disease-free interval \<5 years \[except non-melanoma skin cancer, papillary/follicular thyroid cancer, or cervical carcinoma in situ\] * Active collagen vascular disease, e.g., SLE, scleroderma * Uncontrolled comorbidities: acute cardiovascular disease, substance abuse, or psychiatric disorders

Inclusion Criteria: * Men and women aged 19 years or older as of the date of written informed consent * Patients who have at least one measurable lesion according to RECIST version 1.1 * ECOG performance status ≤ 1 * Patients with life expectancy ≥ 12 weeks * Patients who meet the clinical laboratory test criteria confirming adequate liver, renal, and hematologic function * Patients who voluntarily provide written informed consent to participate in this study * Patients with histologically or cytologically confirmed unresectable advanced solid tumors * Patients who have BRCA1/BRCA2 mutations Exclusion Criteria: * Patients with a medical history of significant illness * Patients with QT interval of \> 450 ms (for men) or \> 460 ms (for women)\\ * Patients who have not yet recovered from toxicity related to previous anticancer therapy * Patients were predicted to demonstrate hypersensitivity to the components of the investigational medicinal product * Patients who have participated in another clinical trial and received an investigational product or medical device * Other individuals deemed inappropriate for participation in the study by the investigator